

## Optimi Health Initiates Pathway to Nasdaq Listing

VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC ("[Donohoe](#) Advisory") to explore strategies to advance towards a potential Nasdaq listing.

Donohoe Advisory ([www.donohoeadvisory.com](http://www.donohoeadvisory.com)), which provides listing related consulting services to public companies and law firms, was formed in 2004 by David A. Donohoe, Jr., former Chief Counsel for the Listing Qualifications Department of The Nasdaq Stock Market. Mr. Donohoe is joined by four ex-Nasdaq and NYSE staff members.

"We welcome the opportunity to work with Optimi," notes Mr. Donohoe. "It's a new, exciting and active sector and there are several industry peers which have achieved senior exchange listing with notable success. We believe Optimi's fundamental approach, business model and early-stage success can pave the way forward to achieve their market ambitions."

Optimi Health's CEO Mike Stier states, "We have long felt that Optimi presents a business combination that could achieve a senior listing. With today's announcement we have begun the next major step towards that goal and are excited by the possibilities ahead."

On Behalf of the Board of Directors, Optimi Health Corp.

Mike Stier  
President, Chief Executive Officer and Director

### **ABOUT OPTIMI** (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer's license under Canada's Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.

Find out more at: <https://optimihealth.ca/>.

### **FOR FURTHER INFORMATION CONTACT:**

Investor Relations  
Email: [investors@optimihealth.ca](mailto:investors@optimihealth.ca)  
Phone: +1 (778) 930-1321  
Web: <https://optimihealth.ca/>

### **FORWARD-LOOKING STATEMENTS**

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements pertaining to the Company's potential Nasdaq listing, the dealer's license application, activities proposed to be conducted under the Company's research exemption and associated business related to Psilocybin and Psilocin and Optimi's plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under "Forward-Looking Statements" and "Risk Factors" in the Company's Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those

contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

***The CSE does not accept responsibility for the adequacy or accuracy of this release.***